Abstract
Aims
To assess the safety and efficacy of phacoemulsification with intravitreal triamcinolone (ivTA) injection in diabetics with cataract and clinically significant macular oedema (CSMO).
Methods
A total of 19 eyes of 15 consecutive diabetic patients with cataract and CSMO were prospectively recruited. Patients underwent phacoemulsification and intraocular lens implantation with 4 mg ivTA injection at completion of surgery. Patients were followed up on day 1, then weekly for 1 month, and thereafter monthly until 6 months postoperatively. Best corrected visual acuity (BCVA), central macular thickness (CMT) measured by optical coherence tomography, and adverse events were recorded.
Results
In total, 17 eyes completed 6 months of follow-up. In all, 58.8% showed improvement in BCVA of ⩾2 lines, with statistically significant improvement in mean Snellen BCVA of 2.4 lines at 6 months. The peak BCVA was achieved at 4 months. The mean CMT decreased from a baseline of 449 μm to a minimum of 321±148 μm (28.5% reduction) achieved at 2 months, with statistically significant reduction at all postoperative time intervals until 6 months. Of 17 eyes, 4 (23.5%) developed transiently elevated intraocular pressure that normalised by 6 months in all but one patient. No injection- or surgery-related complications were encountered.
Conclusions
Phacoemulsification with concurrent 4 mg ivTA injection appears to be a safe option for managing diabetics with cataract and CSMO. However, large-scaled randomised controlled trials are necessary for delineating the relative contributions of cataract removal and CMT reduction to visual improvement. Moreover, the transient effect on CMT may warrant further studies to determine optimal timing and dosage of further ivTA injections.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Gaudric A, Massin-Korobelnik P . Diabetic maculopathy: classification, epidemiology, spontaneous outcome, treatment. Diabetes Metab 1993; 19: 422–429.
Hamilton AMP, Ulbig MW, Polkinghorne P (eds). Epidemiology of diabetic retinopathy. In: Management of Diabetic Retinopathy. BMJ Publishing Group: London, 1996, pp 1–15.
Squirrell D, Bhola R, Bush J, Winder S, Talbot JF . A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. Br J Ophthalmol 2002; 86: 565–571.
Dowler JG, Kulwant SS, Hykin PG, Hamilton PA . The natural history of macular edema after cataract surgery in diabetes. Ophthalmology 1999; 106: 663–668.
Dowler JF, Hykin PG, Hamilton PA . Phacoemulsification versus extracapsular cataract extraction in patients with diabetes. Ophthalmology 2000; 107: 457–462.
Antcliff RJ, Poulson A, Flanagan DW . Phacoemulsification in diabetics. Eye 1996; 10: 737–741.
The Royal College of Ophthalmologists. The Royal College of Ophthalmologists Published Guidelines: Cataract Surgery Guidelines 2001. http://www.rcophth.ac.uk/publications/index.html
Bresnick GH . Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology 1983; 90: 1301–1317.
Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF . Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985; 103: 1567–1569.
Wilson CA, Berkowita BA, Sato Y, Ando N, Handa JT, de Juan Jr E . Treatment with intravitreal steroid reduces blood–retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 110: 1155–1159.
Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J . Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001; 108: 765–772.
Stern AL, Tylor DM, Dalburg LA, Cosentino RT . Pseudophakic cystoid maculopathy: a study of 50 cases. Ophthalmology 1981; 88: 942–946.
Suckling RD, Maslin KF . Pseudophakic cystoid macular oedema and its treatment with local steroids. Aust NZ J Ophthalmol 1998; 16: 353–359.
Jonas JB, Kreissig I, Sofker A, Degenring RF . Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 121: 57–61.
Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991; 98: 766–785.
Lee CM, Olk RJ . Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991; 98: 1594–1602.
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920–927.
Wingate RJ, Beaumont PE . Intravitreal triamcinolone and elevated intraocular pressure. Aust NZ J Ophthalmol 1999; 27: 431–432.
Jonas JB, Kreissig I, Degenring R . Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87: 24–27.
Bakri SJ, Beer PM . The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003; 34: 386–390.
Sutter FK, Gillies MC . Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003; 87: 972–974.
Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA . Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003; 121: 1279–1282.
Benz MS, Murray TG, Dubovy SR, Katz RS, Eifrig CW . Endophthalmitis caused by Mycobacterium chelonae abscesses after intravitreal injection of triamcinolone. Arch Ophthalmol 2003; 121: 271–273.
Ray S, D'Amico DJ . Pseudophakic cystoid macular edema. Semin Ophthalmol 2002; 17: 167–180.
Pollack A, Leiba H, Bukelman A, Oliver M . Cystoid macular oedema following cataract extraction in patients with diabetes. Br J Ophthalmol 1992; 76: 221–224.
Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003; 121: 667–673.
Moshfeghi DM, Kaiser PK, Scott IU, Sears J, Benz M, Sinesterra JP et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 136: 791–796.
Phillips II WB, Tasman WS . Postoperative endophthalmitis in association with diabetes mellitus. Ophthalmology 1994; 101: 508–518.
Author information
Authors and Affiliations
Corresponding author
Additional information
Financial and proprietary interest: Nil
Financial Support: Supported in part by Action for Vision Foundation, Hong Kong
The data in this paper were presented in part as an oral presentation at the fourth Congress of the Asian–Oceanic Glaucoma Society, 1–4 October 2003, Hong Kong
Rights and permissions
About this article
Cite this article
Lam, D., Chan, C., Mohamed, S. et al. Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6-month prospective pilot study. Eye 19, 885–890 (2005). https://doi.org/10.1038/sj.eye.6701686
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6701686
Keywords
This article is cited by
-
Retinal thickness changes due to phacoemulsification in patients with diabetes
Spektrum der Augenheilkunde (2024)
-
Combined phacoemulsification surgery and intravitreal triamcinolone injection versus stand-alone surgery in patients with type 2 diabetes: a prospective randomized trial
BMC Ophthalmology (2022)
-
Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group
Eye (2020)
-
Cataract surgery with combined versus deferred intravitreal dexamethasone implant for diabetic macular edema: long-term outcomes from a real-world setting
Acta Diabetologica (2020)
-
Adjuvant treatment modalities to control macular edema in diabetic patients undergoing cataract surgery
International Ophthalmology (2013)
